Clinical trial
A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are 2 Through 5 Years of Age and Have a CFTR Gating Mutation
NCT01705145 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are 2 Through 5 Years of Age and Have a CFTR Gating Mutation
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 31, 2013
- Completion date
- March 31, 2014
- Enrollment
- 35 (actual)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.